Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma
- PMID: 3967188
- DOI: 10.1002/1097-0142(19850301)55:5<1030::aid-cncr2820550518>3.0.co;2-y
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma
Abstract
The effects of the treatment of multiple myeloma (MM) with APD-bisphosphonate on bone destruction, the dissemination pattern of the MM, and toxicity for normal and malignant cells were investigated in an animal model, the 5T2 MM. This mouse MM very closely resembles the human disease, including the typical bone lesions. It was demonstrated by radiography, microradiography, and histologic investigation that the treatment of the 5T2 MM with APD-bisphosphonate protected the mice against a loss of bone to a significant extent. It seemed that the treatment with APD not only diminished the bone destruction by the MM but also led to the formation of new bone in already-affected bone tissue. The growth pattern of the MM was not substantially influenced by the treatment, even though there was an indication that APD exerts some cytotoxic effect on the MM cells.
Similar articles
-
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.Blood. 1999 Mar 1;93(5):1697-706. Blood. 1999. PMID: 10029599
-
Unwrapping microcomputed tomographic images for measuring cortical osteolytic lesions in the 5T2 murine model of myeloma treated by bisphosphonate.Micron. 2015 Jan;68:107-114. doi: 10.1016/j.micron.2014.10.001. Epub 2014 Oct 13. Micron. 2015. PMID: 25464148
-
Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model.Bone. 2003 Sep;33(3):283-92. doi: 10.1016/s8756-3282(03)00196-0. Bone. 2003. PMID: 13678768
-
Aredia: the once-monthly infusion for the treatment of bone metastases.Curr Opin Oncol. 1998 Aug;10 Suppl 1:S1-5. Curr Opin Oncol. 1998. PMID: 9801852 Review.
-
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.Crit Rev Oncol Hematol. 2011 Feb;77 Suppl 1:S13-23. doi: 10.1016/S1040-8428(11)70004-X. Crit Rev Oncol Hematol. 2011. PMID: 21353176 Review.
Cited by
-
Bone disease in myeloma.Curr Treat Options Oncol. 2001 Jun;2(3):271-83. doi: 10.1007/s11864-001-0041-5. Curr Treat Options Oncol. 2001. PMID: 12057127 Review.
-
Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography.Br J Cancer. 1996 Jun;73(12):1463-5. doi: 10.1038/bjc.1996.277. Br J Cancer. 1996. PMID: 8664113 Free PMC article.
-
An Improved Animal Model of Multiple Myeloma Bone Disease.Cancers (Basel). 2021 Aug 25;13(17):4277. doi: 10.3390/cancers13174277. Cancers (Basel). 2021. PMID: 34503090 Free PMC article.
-
Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.J Cancer Res Clin Oncol. 1986;111(3):209-19. doi: 10.1007/BF00389236. J Cancer Res Clin Oncol. 1986. PMID: 3525574 Free PMC article.
-
Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat--benefit of combining bisphosphonates with cytostatic agents.Invest New Drugs. 1988 Sep;6(3):155-67. doi: 10.1007/BF00175392. Invest New Drugs. 1988. PMID: 3056867
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical